原发性硬化性胆管炎治疗方案的最新进展。
An update on treatment options for primary sclerosing cholangitis.
作者信息
Iravani Shahrokh, Dooghaie-Moghadam Arash, Razavi-Khorasani Niloofar, Moazzami Bobak, Dowlati Beirami Amirreza, Mansour-Ghanaei Alireza, Majidzadeh-A Keivan, Mehrvar Azim, Khoshdel Alireza, Nasiri Toosi Mohssen, Sadeghi Amir
机构信息
Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran.
Gastroenterology and Hepatobiliary Research Center, AJA University of Medical Sciences, Tehran, Iran.
出版信息
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.
Abstract
Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis.
摘要
原发性硬化性胆管炎是一种慢性胆汁淤积性肝病，其特征为胆管树狭窄，最终可导致肝硬化和胆管癌。尽管这种疾病的确切潜在病因尚未完全明确，但据信其病理是由免疫介导机制引起的。越来越多的证据表明有几种治疗方式主要针对该疾病的炎症方面。然而，对于这些患者的最佳治疗方案仍未达成共识。因此，本研究旨在综述原发性硬化性胆管炎患者目前的治疗选择。
相似文献
1
An update on treatment options for primary sclerosing cholangitis.原发性硬化性胆管炎治疗方案的最新进展。
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.
2
Sclerosing cholangitis.硬化性胆管炎
Curr Opin Gastroenterol. 2006 May;22(3):288-93. doi: 10.1097/01.mog.0000218966.78558.67.
3
An overview of recent treatment options for primary sclerosing cholangitis.原发性硬化性胆管炎近期治疗方案概述
Ann Gastroenterol. 2023 Nov-Dec;36(6):589-598. doi: 10.20524/aog.2023.0834. Epub 2023 Oct 30.
4
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.原发性硬化性胆管炎的发病机制及诊治进展。
Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.
5
An update on primary sclerosing cholangitis.原发性硬化性胆管炎的最新进展。
Curr Opin Gastroenterol. 2008 May;24(3):377-83. doi: 10.1097/MOG.0b013e3282f9e239.
6
[Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].[原发性硬化性胆管炎和原发性胆汁性胆管炎的新见解]
Korean J Gastroenterol. 2020 May 25;75(5):246-256. doi: 10.4166/kjg.2020.75.5.246.
7
Primary sclerosing cholangitis: a clinical update.原发性硬化性胆管炎：临床新进展。
Br Med Bull. 2015 Jun;114(1):53-64. doi: 10.1093/bmb/ldv019. Epub 2015 May 16.
8
Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.原发性硬化性胆管炎的 MRI 和 MR 胆胰管成像报告标准：国际原发性硬化性胆管炎研究组磁共振工作组指南。
Eur Radiol. 2022 Feb;32(2):923-937. doi: 10.1007/s00330-021-08147-7. Epub 2021 Aug 6.
9
Primary sclerosing cholangitis.原发性硬化性胆管炎
Semin Gastrointest Dis. 2003 Oct;14(4):189-98.
10
Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.干扰素-γ 依赖性免疫应答有助于小鼠硬化性胆管炎的发病机制。
J Hepatol. 2019 Oct;71(4):773-782. doi: 10.1016/j.jhep.2019.05.023. Epub 2019 Jun 5.
引用本文的文献
1
Investigating shared genetic architecture between inflammatory bowel diseases and primary biliary cholangitis.探究炎症性肠病与原发性胆汁性胆管炎之间的共同遗传结构。
JHEP Rep. 2024 Feb 12;6(6):101037. doi: 10.1016/j.jhepr.2024.101037. eCollection 2024 Jun.
2
Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.溃疡性结肠炎管理指南。波兰胃肠病学会及波兰国家胃肠病学顾问的建议。
Prz Gastroenterol. 2023;18(1):1-42. doi: 10.5114/pg.2023.125882. Epub 2023 Mar 15.
3
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis.多基因全基因组分析鉴定原发性硬化性胆管炎的新易感位点和候选药物。
Nat Commun. 2023 Feb 24;14(1):1069. doi: 10.1038/s41467-023-36678-8.
4
The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.慢性肝病中的肠-肝轴：巨噬细胞的视角。
Cells. 2021 Oct 30;10(11):2959. doi: 10.3390/cells10112959.
5
Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.ω-3 多不饱和脂肪酸：改善熊去氧胆酸反应性的药物-营养治疗方法。
Nutrients. 2021 Jul 29;13(8):2617. doi: 10.3390/nu13082617.
6
Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.自身免疫性胆道疾病：原发性胆汁性胆管炎和原发性硬化性胆管炎。
Pathologica. 2021 Jun;113(3):170-184. doi: 10.32074/1591-951X-245.
本文引用的文献
1
The Role of Melatonin in Colorectal Cancer.褪黑素在结直肠癌中的作用。
J Gastrointest Cancer. 2020 Sep;51(3):748-753. doi: 10.1007/s12029-019-00336-4.
2
Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.抗生素治疗原发性硬化性胆管炎伴或不伴炎症性肠病的效果：系统评价和荟萃分析。
Semin Liver Dis. 2019 Nov;39(4):432-441. doi: 10.1055/s-0039-1688501. Epub 2019 Jul 17.
3
Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.姜黄素治疗原发性硬化性胆管炎的疗效与安全性：一项开放标签的试点研究。
Scand J Gastroenterol. 2019 May;54(5):633-639. doi: 10.1080/00365521.2019.1611917. Epub 2019 May 26.
4
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.维得利珠单抗治疗原发性硬化性胆管炎和炎症性肠病患者的效果。
Clin Gastroenterol Hepatol. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013. Epub 2019 May 14.
5
Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018).原发性硬化性胆管炎诊断与治疗中的重要问题（基于俄罗斯自身免疫性肝炎诊断与治疗共识。莫斯科，2018年）
Ter Arkh. 2019 Mar 17;91(2):9-15. doi: 10.26442/00403660.2019.02.000075.
6
Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions.原发性硬化性胆管炎的磁共振成像——现状和未来方向。
Semin Liver Dis. 2019 Jul;39(3):369-380. doi: 10.1055/s-0039-1687853. Epub 2019 Apr 30.
7
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.生物制剂在炎症性肠病和原发性硬化性胆管炎患者中的应用
Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7.
8
Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.原发性硬化性胆管炎与炎症性肠病合并症：证据更新
Ann Gastroenterol. 2019 Mar-Apr;32(2):124-133. doi: 10.20524/aog.2019.0344. Epub 2019 Jan 15.
9
CCL21-expression and accumulation of CCR7 NK cells in livers of patients with primary sclerosing cholangitis.CCL21 表达和 CCR7+NK 细胞在原发性硬化性胆管炎患者肝脏中的聚集。
Eur J Immunol. 2019 May;49(5):758-769. doi: 10.1002/eji.201847965. Epub 2019 Feb 27.
10
Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.原发性硬化性胆管炎的癌症风险：流行病学、预防和监测策略。
World J Gastroenterol. 2019 Feb 14;25(6):659-671. doi: 10.3748/wjg.v25.i6.659.
Zotero 插件